Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AVITA Medical (RCEL) Depreciation and Depletion (2019 - 2025)

Historic Depreciation and Depletion for AVITA Medical (RCEL) over the last 7 years, with Q4 2025 value amounting to $400000.0.

  • AVITA Medical's Depreciation and Depletion rose 1799.41% to $400000.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $1.6 million, marking a year-over-year increase of 6060.0%. This contributed to the annual value of $1.6 million for FY2025, which is 6000.0% up from last year.
  • According to the latest figures from Q4 2025, AVITA Medical's Depreciation and Depletion is $400000.0, which was up 1799.41% from $421000.0 recorded in Q3 2025.
  • AVITA Medical's 5-year Depreciation and Depletion high stood at $421000.0 for Q3 2025, and its period low was $122000.0 during Q4 2022.
  • Moreover, its 5-year median value for Depreciation and Depletion was $156000.0 (2023), whereas its average is $218000.0.
  • Per our database at Business Quant, AVITA Medical's Depreciation and Depletion plummeted by 2180.85% in 2021 and then surged by 11390.37% in 2025.
  • Quarter analysis of 5 years shows AVITA Medical's Depreciation and Depletion stood at $147000.0 in 2021, then dropped by 17.01% to $122000.0 in 2022, then skyrocketed by 45.9% to $178000.0 in 2023, then skyrocketed by 90.45% to $339000.0 in 2024, then increased by 17.99% to $400000.0 in 2025.
  • Its Depreciation and Depletion stands at $400000.0 for Q4 2025, versus $421000.0 for Q3 2025 and $400000.0 for Q2 2025.